The confirmation of President Joe Biden’s nomination to lead the Centers for Medicare & Medicaid Services (CMS) was delayed by top Senate Republican, Sen. John Cornyn (R-TX), over the recent Texas Medicaid waiver decision.
Gilead Sciences (Gilead) proposed a change to its Advancing Access Patient Assistance Program (PAP), which would require all PAP enrollees to receive their HIV medications (treatment and Pre-Exposure Prophylaxis (PrEP) through mail or courier delivery. This change poses significant challenges for 340B Covered Entities.
H.R.3 would allow the federal government to negotiate directly with drug companies as a way of lowering certain Medicare drug prices; and would give the Secretary of Health and Human Services (HHS) broad authority in determining the price of those particular drugs (250 of them).
The U.S. District Court for the District of Columbia has issued a court order delaying the Department of Health and Human Services’ (HHS) rule #0936-AA08 for almost two years. The rule, which changes payments to Pharmacy Benefit Managers in ways that disallow fluctuations based on the price of a drug, was slated to take effect January 2022.
CMS approved a waiver request from Tennessee that transitions TennCare II enrollees into the TennCare III Medicaid program. It’s been met with community opposition over fears that this program sends the message that “Modified Medicaid Block Grants” and capped spending for enrollees, are (back) on the menu.